| Literature DB >> 30151084 |
Sang Won Park1, Suhrid Banskota2, Pallavi Gurung2, You Jin Jin1, Han-Eol Kang1, Chhabi Lal Chaudhary2, Sang Yeul Lee1, Byeong-Seon Jeong2, Jung-Ae Kim2, Tae-Gyu Nam1.
Abstract
Inflammatory bowel disease (IBD) is an inflammatory disease of the gastrointestinal tract with complex pathogenesis. Here, we synthesized 6-heteroarylamino analogues to inhibit TNF-α-induced adhesion of monocytes to colon epithelial cells which are implicated in the initial inflammation process of IBD. The best analogue, 16a, showed IC50 = 0.29 μM, which is about five orders of magnitude better than that of 5-aminosalicylic acid (5-ASA), a positive control. Oral administration of 6f and 16a dramatically ameliorated 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colon inflammation in rat. The ameliorating effects were accompanied by a high level of recovery in colon and body weights and in the myeloperoxidase (MPO) level. Consistently, the compounds suppressed the expression of intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein 1 (MCP-1). Moreover, they significantly suppressed the expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 while increasing the level of IL-10, an anti-inflammatory cytokine.Entities:
Year: 2018 PMID: 30151084 PMCID: PMC6096353 DOI: 10.1039/c8md00156a
Source DB: PubMed Journal: Medchemcomm ISSN: 2040-2503 Impact factor: 3.597